Inavolisib latest market price in 2025

Inavolisib (Inavolisib) is a targeted therapy drug mainly used to treat patients with certain cancers such as breast cancer, especially those with specific genetic mutations. As an innovative drug, inaliset exerts anti-tumor effects by targeting the PI3K (phosphatidylinositol 3-kinase) pathway and inhibits the growth and spread of cancer cells. Abnormal activation of the PI3K pathway is closely related to the occurrence and progression of various cancers. Therefore, inhibiting this pathway has become an important strategy for cancer treatment.

In the treatment of breast cancer, inalise is mainly used for patients with HER2-negative breast cancer, especially those who have experienced other treatments. The drug slows the growth of tumor cells and reduces the spread of tumors by inhibiting the activity of PI3Kδ isoforms. Inaliset has particular potential to provide an alternative treatment option for patients with advanced or metastatic breast cancer, especially when patients are resistant to other targeted drugs.

Currently, Inalise has been marketed in China and has been approved by the drug regulatory agency. However, due to the short time the drug has been on the market, its price has not yet been made public. The specific selling price of Inalise is still changing and is closely related to its manufacturer, import channels and market demand.

In overseas markets, the price of inalisate is relatively expensive. The price of each box of the original drug may be as high as more than 200,000 yuan. The price fluctuates greatly, mainly affected by exchange rates and international drug pricing strategies. Compared with other cancer treatment drugs, inalise is a high-priced drug, which also makes its price an important issue for patients. Currently, there are no generic versions of Inaliside on the market, so only the original version is on the market, and patients need to pay a relatively high cost when purchasing it.

Reference materials:https://www.itovebi-hcp.com/